Hepatitis C virus research

This study identifies a dimerization site in NS5A that enhances HCV replication fitness by promoting self-interaction, which inhibits NS3 and NS5B activity.

This study identifies the conserved bridging domain on HCV E1E2 as a target for neutralizing antibodies from diverse lineages, showing additivity with neutralizing face antibodies.

This study identifies two classes of HCV E2 neutralizing antibodies from non-human primates immunized with a recombinant E1E2, showing similarity to human antibodies.

This paper develops a HiBiT-expressing recombinant rat hepacivirus that can infect both in vitro and in vivo, enabling quantitative antiviral screening and pathogenicity studies.

The paper designs, characterizes, and tests a soluble HCV E1E2 heterodimer and self-assembling nanoparticles for vaccine development.

This study classifies three structural classes of HCV broadly neutralizing antibodies targeting the E2 front layer supersite and shows their sensitivity to viral polymorphisms.

This study uses cryo-electron tomography to visualize HCV replication structures in near-native conditions, revealing densities within membranous vesicles that may represent viral replication machinery.

This study identifies claudin-3 as an entry factor for rat hepacivirus, showing host-specificity determined by two amino acids in extracellular loop 1.

This study identifies that HCV NS3/4A protease cleaves SPG20, disrupting Itch-mediated degradation of ADRP and promoting lipid droplet formation in infected cells.

This study generates bispecific antibodies targeting two distinct HCV E1E2 epitopes, showing enhanced neutralization breadth and potency compared to monospecific antibodies.

This study analyzes HCV within-host dynamics post-DAA treatment failure, finding persistent viral subpopulations and lineage-specific evolutionary rates.

This study examines how viral fitness and immune responses interact in HCV infection, showing fitness decreases early but rebounds with mutations, and strong CD8+ T-cell responses drive chronic infection.

The paper investigates how E1-E2 interactions in HCV affect viral fitness and antibody escape, identifying mutations and antibodies with implications for vaccine development.

This study identifies HVR-1 as an autoinhibitory region in HCV E1E2 that suppresses viral entry through conformational entropy, which is released upon receptor binding to enhance entry but reduce antibody resistance.

The paper compares RNA extraction methods for HCV detection in plasma, finding magnetic beads-based extraction is suitable for on-site testing while boiling methods have limitations.

The paper identifies a genomic variant in ALPK2 associated with increased liver fibrosis risk in HIV/HCV coinfected women using clinical data from the WIHS cohort.

The paper introduces a required concentration index to rank antiviral efficacy of HCV drug combinations and shows multidrug treatments enhance activity but reduce genotype-specific efficacy.

The paper compares intra-host HCV population characteristics between recent and persistent infections, finding significant differences and developing a machine learning classifier with 95.22% accuracy.

The paper identifies genomic deletions and mutations in Huh7 and Huh7.5.1-8 cell lines that may serve as markers for cell authentication and distinguish between the two lines.

The paper examines how HCV virus subtype and host IFNL4 genotype influence genome-scale RNA structure formation and compositional features in HCV.

This study identifies associations between IFN-lambda polymorphism and HCV variation across multiple genotypes and ancestries, showing viral adaptation to host immune pressure.